FDA Approves QUILLIVANT XR — NextWave Pharmaceuticals, Inc

# FDA Approves NextWave Pharmaceuticals' QUILLIVANT XR for ADHD Treatment NextWave Pharmaceuticals, Inc. received FDA approval for QUILLIVANT XR (methylphenidate hydrochloride), an oral extended-release formulation designed to treat attention-deficit/hyperactivity disorder, positioning the company to capture market share in the competitive ADHD medication segment. The approval expands treatment options for patients seeking once-daily dosing alternatives and could strengthen NextWave's portfolio in the stimulant therapy market.